Lantern Pharma

Lantern Pharma, Inc. engages in the development of drugs through leveraging artificial intelligence, machine learning, and genomic data. Its portfolio includes LP-100, LP-300, and LP-184. The company was founded by Arun K. Asaithambi, Gregory T. Tobin, and Peter L. Nara on November 7, 2013 and is headquartered in Dallas, TX.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Lantern Pharma reports robust Q4 earnings, unveils strategic drug plans

Lantern Pharma's Q4 2022 earnings call highlighted strong financial performance, strategic drug development plans, and a focus on innovation.
The company faces challenges in a competitive landscape but has opportunities in combination therapies, CNS cancer treatments, and engaging key opinion leaders.
Effective financial management and a clear clinical development roadmap are key strengths for Lantern Pharma.
Balancing financial stability with continued investment in research and development will be crucial for sustained growth.

Lantern Pharma advances AI-driven drug development with strong financial backing

Lantern Pharma's Q1 2023 Earnings Call highlighted significant progress in drug development and financial stability, underpinned by a focus on AI and data analytics.
While facing challenges in managing R&D expenses and industry competition, the company's innovative approach and strong cash position position them well for future growth.
Opportunities abound for Lantern Pharma to further leverage AI, explore partnerships, and advance in critical areas like brain cancer drug discovery.
Overall, Lantern Pharma's strategic focus on technology-driven efficiency and innovation sets a promising trajectory for their future in the pharmaceutical landscape.

Lantern Pharma reports promising Q2 results amidst AI-driven advancements

Lantern Pharma's Q2 2023 performance reflects a mix of financial stability, promising drug candidates, and advancements in AI-driven drug development.
The company's strengths lie in its innovative AI-driven strategy, focus on biology, and cost-effective approach to advancing molecules into trials.
Challenges include optimizing trial enrollment, addressing clinician preferences, and navigating the competitive landscape of AI-driven drug discovery.
Opportunities for Lantern Pharma include presenting new data, exploring combination therapies, and leveraging their fit-for-purpose strategy in oncology for future growth.

Lantern Pharma reports Q3 progress, financial stability, and innovation focus

Lantern Pharma's Q3 2023 earnings call highlighted progress in drug development, financial stability with a cash runway into at least Q3 2025, and a focus on innovation through the RADR platform.
While facing challenges such as a net loss and the need to improve financial performance, the company's strengths in pipeline development and technological innovation position them for future growth.
Opportunities lie in leveraging the RADR platform for accelerated drug development, data accumulation in 2024, and pursuing strategic initiatives supported by a strong cash position.
Overall, Lantern Pharma's earnings call reflects a balance of achievements, challenges, and opportunities that shape their trajectory in the pharmaceutical industry.

Lantern Pharma reports Q4 loss, eyes collaborations for growth

Lantern Pharma's Q4 2023 performance reflects a focus on innovation and strategic financial management.
The company's strengths lie in AI-driven drug discovery, diversification efforts, and platform advancements.
Challenges include managing expenses, navigating risks, and ensuring successful execution of growth plans.
Opportunities in collaborations, licensing, and leveraging their platform as a currency offer avenues for expansion.

Lantern Pharma reports Q1 loss, advances AI drug development

Lantern Pharma's Q1 2024 earnings call highlighted financial results, AI-driven drug development, and collaborations.
The company's focus on accelerating drug development and expanding into new indications shows promise for future growth.
Despite challenges in timelines and trial expansions, Lantern Pharma aims for more efficient drug development processes.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

DALLAS--(BUSINESS WIRE)---- $LTRN--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") and machine learning (“M.L.”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that Lantern management will be presenting at two upcoming investor conferences: MicroCap Rodeo Presents: Windy City Roundup in Chicago, IL on Wednesday, October 12 at 10:00 a.m. CT. CEO &

Lantern Pharma to Present at Upcoming Investor Conferences

DALLAS--(BUSINESS WIRE)---- $LTRN--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") and machine learning (“M.L.”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that it will present preclinical data on the potency of Lantern's drug candidate LP-284 for mantle cell lymphoma (MCL) and several other non-Hodgkin's lymphomas at the Society of Hematologic On

Lantern Pharma to Present Positive Preclinical Data on the Efficacy of LP-284 for Mantle Cell Lymphoma at the Society of Hematologic Oncology Annual Meeting

DALLAS--(BUSINESS WIRE)---- $LTRN--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") and machine learning (“M.L.”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that it will host a virtual key opinion leader (KOL) webinar on Sept. 22, 2022 at 12:00 p.m. ET. The webinar will focus on challenges in drug development for pediatric cancers and the potential

Lantern Pharma to Host Virtual KOL Webinar on the Treatment of Pediatric Cancers During Childhood Cancer Awareness Month, featuring Peter Houghton, Ph.D.

DALLAS--(BUSINESS WIRE)---- $LTRN--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") and machine learning (“M.L.”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that it will present positive preclinical data on the in vivo efficacy of its drug candidate LP-184 for pancreatic cancer at the American Association for Cancer Research (AACR) Special Conferen

Lantern Pharma to Present Positive Preclinical Data on the Efficacy of LP-184 for Pancreatic Cancer at the AACR Special Conference for Pancreatic Cancer

DALLAS--(BUSINESS WIRE)---- $LTRN--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") and machine learning (ML) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that the Company's CEO & President, Panna Sharma, will be speaking at H.C. Wainwright's 24th Annual Global Investment Conference, which is being held September 12-14, 2022 in New York, NY. Furt

Lantern Pharma CEO & President, Panna Sharma, to Speak at H.C. Wainwright's 24th Annual Global Investment Conference in September 2022

DALLAS, TX / ACCESSWIRE / August 19, 2022 / RedChip Companies will air a new interview on Lantern Pharma Inc. (NASDAQ:LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") and machine learning ("ML") platform to transform the cost, pace, and timeline of oncology drug discovery and development, on The RedChip Money Report® on Bloomberg TV, this Saturday, August 20, at 7 p.m.

Lantern Pharma Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)

Lantern Pharma Inc. (NASDAQ:LTRN ) Q2 2022 Earnings Conference Call August 8, 2022 4:30 PM ET Company Participants Nicole Leber – Investor Relations Panna Sharma – Chief Executive Officer David Margrave – Chief Financial Officer Conference Call Participants Operator Good afternoon, everyone. I'm Nicole Leber with Investor Relations here at Lantern Pharma.

Lantern Pharma Inc.'s (LTRN) CEO Panna Sharma on Q2 2022 Results - Earnings Call Transcript

DALLAS--(BUSINESS WIRE)---- $LTRN--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") and machine learning (“M.L.”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced operational highlights and financial results for the second quarter ended June 30, 2022. “This quarter was marked with very exciting and important milestones for Lantern as we advance the major

Lantern Pharma Reports Second Quarter 2022 Financial Results and Operational Highlights

DALLAS--(BUSINESS WIRE)---- $LTRN--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence (A.I.) and machine learning (ML) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that it will host its second quarter 2022 financial results webcast on Monday, August 8th, 2022 at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time. Management intends to discuss the operating and fin

Lantern Pharma to Report Second Quarter 2022 Operating & Financial Results on August 8th, 2022 at 4:30 p.m. ET

DALLAS--(BUSINESS WIRE)---- $LTRN--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") and machine learning (“ML”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that the Food and Drug Administration (FDA) has cleared the Company to proceed with its Phase 2 clinical trial, Harmonic™, for its investigational new drug LP-300. The Harmonic™ trial will be a 9

Lantern Pharma Receives FDA Authorization to Initiate its Phase 2 Clinical Trial, Harmonic™, for LP-300 in Never Smokers with Non-Small Cell Lung Cancer

DALLAS , May 12, 2022 /PRNewswire/ -- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") and machine learning (ML) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that it will host a virtual key opinion leader (KOL) webinar on May 26 th, 2022 at 12:00 p.m.

Lantern Pharma to Host Virtual KOL Event on Glioblastoma Multiforme (GBM) with Collaborators from Johns Hopkins during Brain Tumor Awareness Month

DALLAS--(BUSINESS WIRE)---- $LTRN--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") and machine learning (ML) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that the Company's management will be speaking at five investor and scientific conferences in May 2022. Dr. Kishor Bhatia, Lantern's Chief Scientific Officer, will be speaking at the 9th Drug Disco

Lantern Pharma Management to Speak at Multiple Investor and Scientific Conferences in May 2022

Lantern Pharma Inc. (NASDAQ:LTRN ) Q1 2022 Earnings Conference Call May 3, 2022 4:30 PM ET Company Participants Nicole Leber - Investor Relations Associate, Finance & Administrative Coordinator Panna Sharma - President & Chief Executive Officer David Margrave - Chief Financial Officer & Secretary Kishor Bhatia - Chief Scientific Officer & Scientific Consultant Conference Call Participants Nicole Leber Good evening, everybody. I am Nicole Leber with Investor Relations here at Lantern Pharma.

Lantern Pharma Inc. (LTRN) CEO Panna Sharma on Q1 2022 Results - Earnings Call Transcript

RADR®, Lantern's proprietary A.I. and machine learning platform, has now surpassed 20 billion data points, enhancing its precision, insights, and capabilities for oncology drug discovery Launch and enrollment of the HARMONIC™ clinical trial expected in Summer of 2022; the Phase 2 trial is for LP-300 in never-smokers with lung cancer IND application for LP-184 targeted for submission with the FDA in Q3 2022; enabling a first in-human clinical trial for genomically defined solid tumors Announced brain metastases as a new indication being pursued for LP-184 at the American Association of Cancer Research annual meeting Advanced preclinical studies are underway in Australia, through Australian subsidiary, Lantern Pharma Australia Pty Ltd.

Lantern Pharma Reports First Quarter 2022 Financial Results and Operational Highlights

DALLAS , April 26, 2022 /PRNewswire/ -- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence (A.I.) and machine learning (ML) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that Maria L.

Lantern Pharma's Board of Directors Names Maria Maccecchini, Ph.D. as a Director Nominee to Lantern's Board of Directors

DALLAS, April 22, 2022 /PRNewswire/ -- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence (A.I.) and machine learning (ML) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that it will report its first quarter 2022 financial results on Tuesday, May 3, 2022, after the financial markets close.

Lantern Pharma to Report First Quarter 2022 Operating & Financial Results on May 3rd, 2022 at 4:30 p.m. ET

ORLANDO, FL / ACCESSWIRE / April 14, 2022 / RedChip Companies, Inc. today announced that Lantern Pharma (NASDAQ:LTRN),a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") and machine learning (ML) platform to transform the cost, pace, and timeline of oncology drug discovery and development, will appear on The RedChip Money Report® on Bloomberg TV, April 16, at 7 p.m.

Lantern Pharma Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)

DALLAS , March 22, 2022 /PRNewswire/ -- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") and machine learning (ML) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that its Board of Directors has authorized an extension through July 31, 2022 of Lantern's existing share repurchase program to acquire up to $7 million of the Company's common stock.

Lantern Pharma Announces Extension of Existing Share Repurchase Program

LP-184 demonstrated anti-tumor activity in brain metastases cell models from lung, skin, and breast cancers. Brain metastases in the U.S. can occur in 10-30% of all cancer cases and are diagnosed in over 100,000 patients each year.

Lantern Pharma to Present Positive Preclinical Data on the Effectiveness of LP-184 in Brain Metastases at the American Association of Cancer Research (AACR) Annual Meeting

Lantern Pharma Inc.'s (LTRN) CEO Panna Sharma on Q4 2021 Results - Earnings Call Transcript

DALLAS, March 10, 2022 /PRNewswire/ -- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") and machine learning (ML) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced financial results and operational highlights for the fourth quarter and fiscal year ended December 31, 2021.

Lantern Pharma Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Operational Highlights

DALLAS , March 3, 2022 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, announced today that it will host a conference call on Thursday, March 10th, 2022 at 4:30 p.m.

Lantern Pharma Inc. to Report Fourth Quarter and Full Year 2021 Financial Results on March 10, 2022

DALLAS, Feb. 15, 2022 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a Dallas-based clinical stage biopharmaceutical company using its proprietary artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that it is expanding opportunities for its portfolio of drug candidates and A.I.

Lantern Pharma Expands into Additional Pediatric Cancers Through a Collaboration with The Greehey Children's Cancer Research Institute (GCCRI) at University of Texas Health Science Center-San Antonio

The FDA has granted Rare Pediatric Disease and Orphan Drug Designations to Lantern Pharma Inc's (NASDAQ: LTRN) LP-184 for Atypical Teratoid Rhabdoid Tumor (ATRT), a form of cancer of the Central Nervous System. LP-184 is a small molecule drug candidate and next-generation alkylating agent that preferentially damages DNA in cancer cells that over-express certain biomarkers or harbor mutations in DNA repair pathways.

Lantern Pharma's LP-184 Receives Rare Pediatric, Orphan Drug Tags For Rare Form Of Cancer

DALLAS, Jan. 24, 2022 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology drug discovery and development today announced that the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation and Orphan Drug Designation for the company's drug candidate LP-184 for the treatment of pediatric patients with ATRT.

Lantern Pharma Receives Rare Pediatric Disease and Orpan Drug Designations for LP-184 for the Treatment of Atypical Teratoid Rhabdoid Tumor (ATRT) - an Aggressive and Rapidly Growing Form of Cancer of the Central Nervous System

News for Lantern Pharma Stock (LTRN)